EUVIMEDEUVIMED felfedezése
Open access · CC BY-NC-ND 4.0

Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase

JingCheng Zhang, Sheng Zhou, SiSi Jiang, Fang He, Yan Tu, HuiXian Hu

Journal of Cancer Research and Clinical Oncology · 2024

DOI: 10.1007/s00432-024-05939-4 ↗

At a glance

Journal article in Journal of Cancer Research and Clinical Oncology, 2024. Written by JingCheng Zhang and 5 co-authors. Institution: Department of Hematology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, China. Major MEDLINE topics: Imatinib Mesylate, Cytidine Deaminase, Proto-Oncogene Proteins c-myc, Xenograft Model Antitumor Assays. Cited 1 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbsztraktSubjectsBibliográfiai adatokCiteRelated studies

Abstract (original language)

BACKGROUND: Double-hit lymphoma (DHL) with c-MYC gene translocation is highly aggressive and has a poor prognosis. In DHL cells, activation-induced cytidine deaminase (AID) promotes antibody class switch recombination (CSR), ultimately leading to c-MYC gene translocation caused by Myc/IgH DNA double-strand breaks. However, currently there is still no method to suppress the expression of AID. METHODS: In this study, we compared the clinical significance of AID expression in DHL, Additionally, two human double-hit lymphoma cell lines were used to analyze the effect of imatinib mesylate on c-MYC in vitro, and the therapeutic effect was also evaluated in xenograft mouse models. RESULTS: Imatinib mesylate downregulated the AID and c-MYC proteins in patients with chronic myelogenous leukemia associated with DHL. In addition, imatinib mesylate reduced AID and c-MYC expression in SU-DHL-4 and OCI-Ly18 DHL cells. Imatinib mesylate exerted significant inhibitory effects on the proliferation and metastasis of SU-DHL-4 and OCI-Ly18 cells. Finally, imatinib mesylate reduced not only tumor burden in DHL mouse models, but also AID and c-MYC expression in vivo. CONCLUSION: These findings reveal that imatinib mesylate effectively reduces the carcinogenic function of c-MYC in DHL, providing novel strategies for developing therapies targeting c-MYC-driven DHL.

Subjects

MeSH terms (MEDLINE)

Imatinib MesylateCytidine DeaminaseProto-Oncogene Proteins c-mycXenograft Model Antitumor AssaysAnimalsHumansMiceCell Line, TumorLeukemia, Myelogenous, Chronic, BCR-ABL PositiveFemaleAntineoplastic AgentsTranslocation, GeneticMaleCell ProliferationLymphomaGene Expression Regulation, NeoplasticAICDA (Activation-Induced Cytidine Deaminase)

Author keywords

Activation-induced cytidine deaminaseC-MycDiffuse large B-cell lymphomaDouble-hit lymphomaImatinib mesylate

Substances

Imatinib MesylateCytidine DeaminaseProto-Oncogene Proteins c-mycMYC protein, humanAICDA (Activation-Induced Cytidine Deaminase)Antineoplastic Agents

Authors and institutions

  • Department of Hematology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, China.
  • Department of Hematology, Lanxi People's Hospital, Lanxi, 321100, China.
  • Department of Internal Medicine, Yongkang Traditional Chinese Medicine Hospital, Yongkang, 321000, China.
  • Department of Hematology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, China. huhuixian@zju.edu.cn.

Cite

APA

Zhang, J., Zhou, S., Jiang, S., He, F., Tu, Y., & Hu, H. (2024). Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05939-4

Vancouver

Zhang J, Zhou S, Jiang S, He F, Tu Y, Hu H. Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05939-4

BibTeX
@article{Zhang2024,
  author = {Zhang, JingCheng and Zhou, Sheng and Jiang, SiSi and He, Fang and Tu, Yan and Hu, HuiXian},
  title = {Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  doi = {10.1007/s00432-024-05939-4}
}
Start for free →